Loading…
Alivus Life Sciences (ALIVUS)₹1,474−5.41%Pharmaceuticals
At the end of the Jun 2026 quarter, Alivus Life Sciences' shareholders were: promoters 74.86%, FIIs 5.50%, DIIs 7.15%, public 12.49%. Promoter holding is unchanged on the quarter. FII holding is down 0.88 percentage points from 6.38% a year earlier. 0.00% of promoter shares were pledged. It had 1,25,516 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 82.84% | 82.84% | 82.84% | 82.84% | 74.99% | 74.99% | 74.98% | 74.93% | 74.90% | 74.90% | 74.86% | 74.86% |
| FIIs | 4.36% | 4.54% | 4.98% | 4.78% | 7.81% | 6.70% | 6.53% | 6.38% | 6.80% | 5.05% | 5.27% | 5.50% |
| DIIs | 0.64% | 0.74% | 1.40% | 1.56% | 4.14% | 4.84% | 5.16% | 5.59% | 5.44% | 7.10% | 7.24% | 7.15% |
| Public | 12.16% | 11.88% | 10.78% | 10.82% | 13.06% | 13.47% | 13.33% | 13.10% | 12.86% | 12.95% | 12.63% | 12.49% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 0.00% |
| Number of shareholders | 1,98,695 | 1,85,467 | 1,56,129 | 1,49,344 | 1,43,910 | 1,46,789 | 1,41,928 | 1,38,452 | 1,35,596 | 1,32,702 | 1,27,925 | 1,25,516 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Nirma Limited | Promoter | 74.90% | 0.00 |
| Quant Mutual Fund - Quant Small Cap Fund | DII | 2.50% | 0.00 |
| Government Pension Fund Global | FII | 2.42% | +0.06 |
| Massachusetts Institute of Technology | FII | 1.24% | 0.00 |
| ICICI Prudential Pharma Healthcare and Diaganostic | DII | Exited | — |
Promoters held 74.86% of Alivus Life Sciences at the end of the Jun 2026 quarter, down 0.07 percentage points from 74.93% a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 5.50% (up 0.23 percentage points from 5.27% a quarter earlier) and domestic institutions (DIIs) held 7.15% (down 0.09 percentage points from 7.24% a quarter earlier).
No. The Jun 2026 filing shows no pledged promoter shares.
Alivus Life Sciences had 1,25,516 shareholders at the end of the Jun 2026 quarter, against 1,38,452 a year earlier.
Quant Mutual Fund - Quant Small Cap Fund (DII) held 2.50% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.